{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'Table 5 - Summary of adverse event reporting instructions', 'Event', 'Reporting', 'Specific events in this category', 'Case Report Form completion', 'category', 'timeframe', 'AE form', 'Safety', 'Other', 'Complementary', 'specific', 'Form', 'forms', 'Adverse Event', 'Routine', 'Any AE that is not SAE or AESI', 'Yes', 'No', 'No', '(non-SAE,', 'non-AESI)', 'Serious Adverse', 'Expedited', 'Any AE meeting seriousness criterion per', 'Yes', 'Yes', 'No', 'Event (non-AESI', '(within 24 hours)', 'Section 10.4.1.2', 'or AESI)', 'Adverse Event of', 'Expedited', 'Pregnancy', 'Yes', 'Yes', 'Yes', 'Special Interest', '(within 24 hours)', 'Symptomatic overdose with IMP', 'Yes', 'Yes', 'No', 'ALT increase as defined in the protocol', 'Yes', 'Yes', 'Yes', 'QTc >500ms', 'Yes', 'Yes', 'No', 'Hypotension/orthostatic hypotension', 'Yes', 'Yes', 'No', '(asymptomatic and symptomatic)', '10.5 OBLIGATIONS OF THE SPONSOR', 'During the course of the study, the Sponsor will report in an expedited manner:', 'All SAEs that are both unexpected and at least reasonably related to the IMP (SUSAR), to', 'the regulatory authorities, independent ethics committee (IECs)/institutional review boards', '(IRBs) as appropriate and to the Investigators.', 'All SAEs that are expected and at least reasonably related to the IMPs to the regulatory', 'authorities, according to local regulations.', \"Adverse events that are considered expected will be specified by the investigator's brochure.\", \"Any other AE not listed as an expected event in the Investigator's Brochure or in this protocol\", 'will be considered unexpected.', 'For regulatory purposes, the treatment code will be unblinded at Sponsor Pharmacovigilance', 'department level for reporting to the Health Authorities of any suspected unexpected adverse drug', 'reaction (SUSAR) and reasonably associated with the use of the IMP according to either the', 'judgment of the Investigator and/or the Sponsor. Apart from Sponsor Pharmacovigilance', 'department, within the company and associated organizations, the results of this unblinding will', 'remained undisclosed.', 'The Sponsor will report all safety observations made during the conduct of the trial in the clinical', 'study report.', 'Property of the Sanofi Group - strictly confidential', 'Page 75', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '10.6 SAFETY INSTRUCTIONS', 'In case of signs or symptoms suggestive of hypotension or orthostatic hypotension occur, physical', 'examinations will include respiratory, cardiovascular systems; clinical management of this', 'hypotension should be undertaken by the investigator. If the event persisted, decision of IMP', 'discontinuation should be discussed with the Sponsor.', '10.7 ADVERSE EVENTS MONITORING', 'All events will be managed and reported in compliance with all applicable regulations, and', 'included in the final clinical study report.', 'Property of the Sanofi Group - strictly confidential', 'Page 76', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '11', 'STATISTICAL CONSIDERATIONS', '11.1', 'DETERMINATION OF SAMPLE SIZE', 'The sample size calculations are based on the primary efficacy variable of uncorrected global', 'CFR assessed by 13N-ammonia or PET scan change from baseline to Week 4.', 'Assumptions for sample size calculation:', 'A large study of 2783 patients referred for rest/stress positron emission tomography', 'suggested a SD 0.65 for CFR at baseline. With the hypothesis of correlation of', '0.6 between baseline assessment and Week 4 assessment the SD for the change of baseline', 'to week for could be estimated at 0.58', 'A t-test at a 1-sided 5% significance level.', 'Based on the above assumptions, 35 evaluable patients per arm are needed for this study to detect', 'a treatment effect of 0.35 with 80% of power. 10% more patients will be randomized in each', 'group. Thus, approximately 78 patients will be randomized in this study, 39 per arm.', 'Calculations were made using East 6.3.', '11.2 DISPOSITION OF PATIENTS', 'Screened patients are defined as any patient who originally met the inclusion criteria and signed', 'the informed consent.', 'Randomized patients consist of all screened patients with a double-blind treatment kit number', 'allocated and recorded in the IVRS/IWRS database, regardless of whether the treatment kit was', 'used or not.', 'Patients treated without being randomized will not be considered as randomized and will not be', 'included in any efficacy population. The safety experience of patients treated and not randomized', 'will be reported separately, and these patients will not be in the safety population.', 'For any patient randomized more than once, only the data associated with the first randomization', 'will be used in any analysis population. The safety experience associated with any later', 'randomization will be assessed separately.', 'Property of the Sanofi Group - strictly confidential', 'Page 77', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}